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Nitro/Nitrosyl-Ruthenium Complexes Are Potent and Selective Anti-
Trypanosoma cruzi Agents Causing Autophagy and Necrotic Parasite
Death
Tanira M. Bastos,a Marília I. F. Barbosa,b Monize M. da Silva,b José W. da C. Júnior,b Cássio S. Meira,a Elisalva T. Guimaraes,a,c
Javier Ellena,d Diogo R. M. Moreira,a,e Alzir A. Batista,b Milena B. P. Soaresa,e
FIOCRUZ, Centro de Pesquisas Gonçalo Moniz, Salvador, Bahia, Brazila; UFSCAR, Departamento de Química, São Carlos, São Paulo, Brazilb; UNEB, Departamento de
Ciências da Vida, Salvador, Bahia, Brazilc; USP, Instituto de Física de São Carlos, São Carlos, São Paulo, Brazild; Centro de Biotecnologia e Terapia Celular, Hospital São Rafael,
Salvador, Bahia, Brazile
cis-[RuCl(NO2)(dppb)(5,5=-mebipy)] (complex 1), cis-[Ru(NO2)2(dppb)(5,5=-mebipy)] (complex 2), ct-[RuCl(NO)(dppb)(5,5=-
mebipy)](PF6)2 (complex 3), and cc-[RuCl(NO)(dppb)(5,5=-mebipy)](PF6)2 (complex 4), where 5,5=-mebipy is 5,5=-dimethyl-
2,2=-bipyridine and dppb is 1,4-bis(diphenylphosphino)butane, were synthesized and characterized. The structure of complex 2
was determined by X-ray crystallography. These complexes exhibited a higher anti-Trypanosoma cruzi activity than benznida-
zole, the current antiparasitic drug. Complex 3 was the most potent, displaying a 50% effective concentration (EC50) of 2.1 0.6
Magainst trypomastigotes and a 50% inhibitory concentration (IC50) of 1.3 0.2Magainst amastigotes, while it displayed a
50% cytotoxic concentration (CC50) of 51.4 0.2M inmacrophages. It was observed that the nitrosyl complex 3, but not its
analog lacking the nitrosyl group, releases nitric oxide into parasite cells. This release has a diminished effect on the trypano-
somal protease cruzain but induces substantial parasite autophagy, which is followed by a series of irreversible morphological
impairments to the parasites and finally results in cell death by necrosis. In infected mice, orally administered complex 3 (five
times at a dose of 75mol/kg of body weight) reduced blood parasitemia and increased the survival rate of the mice. Combina-
tion index analysis of complex 3 indicated that its in vitro activity against trypomastigotes is synergic with benznidazole. In ad-
dition, drug combination enhanced efficacy in infected mice, suggesting that ruthenium-nitrosyl complexes are potential con-
stituents for drug combinations.
Chagas disease, caused by the protozoan parasite Trypanosomacruzi, affects approximately 10 million people worldwide,
with a high prevalence in Latin America (1). The main drugs used
against this disease are benznidazole and nifurtimox (2), both of
which are effective in curing the disease when administered dur-
ing the acute phase but are less effective in patients that have
progressed to the chronic phase (3). Furthermore, these drugs are
not considered ideal, due to severe side effects, and drug resistance
to T. cruzi strains has been reported (4). Thus, research aimed at
identifying molecules with anti-T. cruzi activity is urgently need
for the treatment of Chagas disease.
In recent years, a variety of anti-T. cruzi drug targets have been
identified, including the enzymes lanosterol 14-demethylase,
trans-sialidase, trypanothione reductase, and cysteine protease
(5). T. cruzi contains a cysteine protease homologous to cathepsin
L in mammalian cells, called cruzipain or cruzain, which is re-
sponsible primarily for the proteolytic activity involved in all
stages of the parasite’s life cycle (6, 7). Cruzain is important for
parasite survival, cell growth, and differentiation (8, 9). Further-
more, this enzyme plays an important role in the process of para-
site internalization in mammalian cells and in the intracellular
replication of T. cruzi (7, 9).
Nitric oxide (NO) is a well-known endogenous trypanocidal
molecule which contributes to host control of acute infection (10,
11). NO inactivates cruzain by S-nitrosylation of the binding site
(12), butT. cruzi uses trypanothione reductase to convert NO into
a harmless species (13). Therefore, it has been hypothesized that
NO donor drugs may be useful against T. cruzi infection by pro-
ducing exogenous NO (14). Organic NO donor molecules have
been investigated as anti-T. cruzi agents, but compounds with in
vivo efficacy have not been identified (15). In recent years, ruthe-
nium-nitrosyl complexes have been evaluated as anti-T. cruzi
agents, demonstrating potent and selective antiparasitic activity,
including in T. cruzi-infected mice (16–19). In addition, this class
of complexes exhibited inhibitory activity against theT. cruzi glyc-
eraldehyde 3-phosphate dehydrogenase, suggesting that rutheni-
um-nitrosyl complexes may have pleiotropic effects (19). From
the point of view of medicinal chemistry, ruthenium complexes
have been explored as an alternative to platinum complexes in the
context of anticancer and anti-infective chemotherapy (20–22).
More specifically, ruthenium complexes are described as out-
standing bioactive agents because of the phosphine ligands, which
provide great stability for these compounds (23–26). Neverthe-
less, only a few ruthenium complexes containing these ligands
have been fully examined against T. cruzi (19).
Therefore, in this studyweevaluated the invitroand invivoanti-T.
cruzi activity of four new ruthenium complexes: cis-[RuCl
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(NO2)(dppb)(5,5=-mebipy)] (complex 1), cis-[Ru(NO2)2(dppb)
(5,5=-mebipy)] (complex 2), ct-[RuCl(NO)(dppb)(5,5=-mebipy)]
(PF6)2 (complex 3), and cc-[RuCl(NO)(dppb)(5,5=-mebipy)]
(PF6)2 (complex 4). All the synthesized compounds aremononuclear
complexes and contain 5,5=-dimethyl-2,2=-bipyridine (5,5=-me-
bipy) and 1,4-bis(diphenylphosphino)butane (dppb) ligands. To
ascertain the importance of the nitrosyl group in antiparasitic ac-
tivity, the synthesized complexes contained a nitrosyl group in
two different positions (cis and trans), and two complexes con-
tained a nitro group in the place of nitrosyl. Also, a complex lack-
ing the nitro/nitrosyl groups, cis-[RuCl2(dppb)(bipy)] (complex
5), was prepared and tested. By testing complexes 1 to 5 in vitro, a
potent anti-T. cruzi activity was observed in the nitro/nitrosyl
complexes (1 to 4), which was higher than that observed for ben-
znidazole. In contrast, complex 5 did not show antiparasitic activ-
ity. Complex 3, the most potent compound, exhibited strong
trypanocidal activity, through the release of NO, which subse-
quently induced the formation of vacuoles typical of the au-
tophagy process. Moreover, complex 3 decreased blood para-
sitemia in T. cruzi-infected mice, strengthening the hypothesis
that ruthenium complexes are promising drugs for Chagas disease
therapy.
MATERIALS AND METHODS
Synthesis and drug dilution. Synthesis, structural characterization, and
X-ray analysis of complexes 1 to 5 are described in the supplemental
material. All complexes as well as the reference drugs were dissolved in
dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA) and
then diluted in cell culture medium. The final concentration of DMSO
was less than 1% in all in vitro experiments.
Animals. Female BALB/c mice (18 to 20 g) were maintained in steril-
ized cages under a controlled environment, receiving a rodent balanced
diet and water ad libitum at Centro de Pesquisas Gonçalo Moniz (Funda-
ção Oswaldo Cruz, Bahia, Brazil). All experiments were carried out in
accordance with the recommendations of Ethical Issues Guidelines and
were approved by the local Animal Ethics Committee (protocol number
002/2011).
Parasites. All experiments were performed with the Y strain of T.
cruzi. The epimastigote form was maintained in axenic medium at 28°C,
with weekly transfers into liver infusion tryptose (LIT) medium supple-
mented with 10% fetal bovine serum (FBS; Cultilab, Campinas, Brazil),
1% hemin (Sigma-Aldrich), 1% R9 medium (Sigma-Aldrich), and 50
g/ml of gentamicin (Novafarma, Anápolis, Brazil). For in vitro assays,
the metacyclic trypomastigote form of T. cruzi was obtained from the
supernatant of infected LLC-MK2 cells and maintained in RPMI 1640
medium (Sigma-Aldrich) supplemented with 10%FBS (Cultilab, Campi-
nas, Brazil) and 50 g/ml of gentamicin (Novafarma, Anápolis, Brazil) at
37°C with 5% CO2. For in vivo assays, bloodstream trypomastigotes were
obtained from infected BALB/c mice at the peak of parasitemia.
Activity against epimastigotes.The effect of the treatment on epimas-
tigotes proliferation was observed 5 days after incubation with the com-
plexes at six concentrations. Epimastigote forms were resuspended at 5
106 cells/ml in supplemented LITmedium.The number of viable parasites
was counted in a hemocytometer, and complex activity was expressed as
50% inhibitory concentration (IC50), in comparison to untreated para-
sites. Each drug concentration was carried out in triplicate, and three
independent experiments were performed. The reference drug, benznida-
zole (Lafepe, Pernambuco, Brazil), was used as the positive control.
Activity against trypomastigotes. Trypomastigotes were cultured in
96-well plates (2 106 cells/ml) in enriched RPMI 1640 medium, in the
presence or absence of the complexes at different concentrations for 24 h.
Viable parasites were counted in a hemocytometer, and complex activity
was expressed as 50% effective concentration (EC50), in comparison to
untreated parasites. Each drug concentration was carried out in triplicate,
and three independent experiments were performed. The reference drug,
benznidazole, was used as the positive control. For in vitro drug combi-
nations, doubling dilutions of each drug (ruthenium complex 3 and ben-
znidazole) used alone or in fixed combinations were incubated with 2
106 cells/ml trypomastigotes for 24 h. The analysis of the combined effects
was performed by calculating the median effect principle using Com-
puSyn software.
Host cell toxicity. Five days after 3% sodium thioglycolate injection
(Sigma-Aldrich), macrophages were obtained by washing with saline so-
lution in the peritoneal cavity of BALB/c mice. Macrophages in RPMI
1640medium supplemented with 10% FBS were seeded on 96-well plates
at 5  105 cells/ml and treated with the complexes for 6 h or 24 h of
incubation time. Following this, cells were washed with phosphate-buff-
ered saline (PBS) twice, and cell viability was determined by alamarBlue
assay (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Colorimetric readings were performed after 10 h at 570 and
600 nm. Fifty-percent cytotoxic concentration (CC50) values were calcu-
lated using data points gathered from three independent experiments.
In vitro T. cruzi infection assay. Peritoneal macrophages stimulated
with 3% sodium thioglycolate (Sigma-Aldrich) were transferred to 24-
well plates at 2 105 cells/well in supplemented RPMI 1640medium and
maintained overnight at 37°C with 5% CO2. The cultures were washed
with saline solution and infectedwith trypomastigotes (10 parasites:1 host
cell). Following 2 h of incubation, the noninternalized parasites were re-
moved by washing with saline solution, and fresh medium, with or with-
out drugs (25, 10, 5, and 1.0M),was added to the cultures and incubated
for 6 h. Afterward, the culture was washed with saline, and drug-free
medium was added and incubated for 4 days. Cells were fixed in absolute
ethanol, stained with hematoxylin and eosin, and analyzed in an optical
microscope (Olympus, Tokyo, Japan). The percentage of infectedmacro-
phages and the percentage of intracellular parasites per 100 macrophages
were determined and compared to the negative control. The IC50 of pro-
liferation inhibition of amastigotes was calculated using the number of
parasites/100 cells. The reference drug, benznidazole, was used as the pos-
itive control. Each drug concentration was carried out in triplicate, and
three independent experiments were performed.
Cruzain inhibition. Recombinant cruzain was activated in acetate
buffer (0.1 M; pH 5.5) containing 5.5 mM dithiothreitol (DTT) (Invitro-
gen), and the protein concentration was adjusted to a final concentration
of 0.1 M. Protein was incubated in phosphate buffer containing 0.01%
Triton 100 and transferred to a 96-well plate. Following complex addition,
the plate was incubated for 10 min at 35°C. A solution containing the
Z-FR-AMC (Sigma-Aldrich) protease substrate was then added, incu-
bated for 10 min, and read using the EnVision multilabel reader
(PerkinElmer, Connecticut, USA). The percentage of cruzain inhibition
was calculated by using the following equation: 100  (A1/A  100),
where A1 represents the cruzain relative fluorescence units (RFU) in the
presence of the test inhibitor and A refers to the control RFU (cruzain and
substrate only). IC50s of cruzain activity inhibition were also calculated.
(2S,3S)-trans-Epoxysuccinyl-L-leucylamido-3-methylbutane (E-64c) (Sig-
ma-Aldrich) was used as the reference cruzain inhibitor. Each drug concen-
tration was carried out in triplicate, and two independent experiments were
performed.
Nitric oxide production.Peritonealmacrophages stimulatedwith 3%
sodium thioglycolate (106 cells/well) were incubated in a 24-well plate and
infected with trypomastigotes (106 parasites/well) for 2 h. This experi-
ment was also performed using J774 macrophages at 106 cells/well, which
were incubated in a 24-well plate and infected with trypomastigotes (2
105 parasites/well) for 3 h. Cells were washed with saline solution and
treated with complex 3 or 5 at a concentration of 10 M for 24 h. For the
positive control, cells were stimulatedwith 5.0 ng/ml of gamma interferon
(IFN-; R&D Systems, Minneapolis, MN, USA) and 500 ng/ml of lipo-
polysaccharide (LPS; Sigma-Aldrich). Nitrite levels were determined 24 h
after incubation using the Griess method (27).
Trypanocidal Ruthenium Complexes
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Transmission and scanning electron microscopy analysis. Trypo-
mastigotes (107 cells/ml) were treated with 2.1 M complex 3 and incu-
bated for 24 h at 37°C with 5% CO2. Infected macrophages were treated
with 2.1 M complex 3 and incubated for 6 h. After incubation, parasites
were fixed for 1 h at room temperature with 2% formaldehyde and 2.5%
glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) in so-
dium cacodylate buffer (0.1M, pH 7.2). Fixed parasites were then washed
4 times with sodium cacodylate buffer (0.1M, pH 7.2) and postfixed with
a 1% solution of osmium tetroxide (Sigma-Aldrich). The cells were dehy-
drated in an ascending acetone series (30, 50, 70, 90, and 100%) and
embedded in PolyBed resin (PolyScience Family, Warrington, PA, USA).
Ultrathin sections were prepared on a Leica UC7 ultramicrotome and
collected on 300-mesh copper grids, contrasted with uranyl acetate and
lead citrate. Images were captured in a JEOL TEM-1230 transmission
electron microscope. Alternatively, trypomastigotes were dried by using
the critical-pointmethodwith CO2,mounted on aluminum stubs, coated
with a 20-nm-thick gold layer, and examined under a JEOL JSM-6390LV
scanning electron microscope.
Monodansylcadaverine labeling. Trypomastigotes (107 cells/ml)
were treated with complex 3 at a concentration of 2.1 M. After incuba-
tion for 24 h, 0.05 mM monodansylcadaverine (MDC; Sigma-Aldrich)
was added and incubated for 15 min in the absence of light. For the
positive control, cells were treated with 0.1 mg/ml of rapamycin (Sigma-
Aldrich). The autophagy inhibitorwortmannin (Sigma-Aldrich)was used
at 0.5 M and added simultaneously with complex 3 to the cell culture.
The parasites were washed twice with PBS and analyzed in an FV1000
confocal microscope (Olympus).
LC3B immunolocalization. Infected macrophages (as described
above) were treated with complex 3 at a concentration of 2.1M. Follow-
ing 6 h of incubation, cells were washed in PBS and fixed with 4% para-
formaldehyde (Electron Microscopy Sciences) for 20 min, permeabilized
with 0.2% Triton X-100 (Sigma-Aldrich) in PBS for 15 min at room tem-
perature, and blocked with background blocker (Diagnostic BioSystem,
Pleasanton, CA, USA). Cells were incubated overnight with rabbit poly-
clonal antibody against LC3B (Invitrogen) (1/100 dilution) diluted in 1%
PBS-bovine serum albumin (BSA), rinsed, and incubated for 1 h at room
temperature with Alexa Fluor 568-conjugated goat anti-rabbit IgG (Mo-
lecular Probes, Carlsbad, CA, USA) diluted to 1:400. Subsequently, cells
were washed in PBS and mounting medium with 4=,6-diamidino-2-phe-
nylindole (DAPI) (Vector Laboratories, Burlingame, CA, USA). Cells
were analyzed by confocal microscopy (FV1000; Olympus).
Flow cytometry analysis. Trypomastigotes (107 cells/ml) were resus-
pended in supplemented RPMI 1640medium and treated with complex 3
(2.1 or 5 M) for 36 h at 37°C with 5% CO2. Parasites were labeled with
propidium iodide (PI) and annexin V using the annexin V-fluorescein
isothiocyanate (FITC) apoptosis detection kit (Sigma-Aldrich) according
to the manufacturer’s instructions. The experiment was performed using
a BD FACSCalibur flow cytometer (San Jose, CA, USA) by acquiring
10,000 events, anddatawere analyzed byBDCellQuest software (San Jose,
CA, USA).
In vivo anti-T. cruzi activity. Female BALB/c mice (18 to 20 g) were
infected by intraperitoneal injection of 104 bloodstream trypomastigotes
of the T. cruzi Y strain in a 100-l solution per mouse. Only mice with
positive blood parasitemia were included in the experiment. Each drug
was solubilized inDMSO-saline (10:90 [vol/vol]) prior to administration.
Mice were randomly divided into groups (n 6 mice per group). Treat-
ment was initiated within 5 days postinfection and given once per day
orally by gavage for five consecutive days. Complex 3 doses were admin-
istered at 25 (26.6 mg/kg of body weight) or 75 mol/kg (80 mg/kg), and
benznidazole was given at 384 mol/kg (100 mg/kg). According to rec-
ommendations (28, 29), the following parameters were evaluated: (i) mi-
croscopic parasitemia analysis at 5, 8, 10, and 12 days postinfection and
(ii) animal survival 30 days postinfection. The percentage of parasitemia
reduction was calculated as follows: [(average vehicle group  average
treated group)/average vehicle group] 100%. Two independent exper-
iments were carried.
In vivo drug combinations. The same in vivo protocol described
above was performed. The four groups included were (i) vehicle DMSO-
saline (10:90 [vol/vol]), (ii) complex 3 alone at 75 mol/kg (80 mg/kg),
(iii) benznidazole alone at 38mol/kg (10mg/kg), and (iv) simultaneous
treatment with complex 3 at 75mol/kg and benznidazole at 38mol/kg.
Two independent experiments were performed.
Statistical analyses. Nonlinear regression analysis was used to calcu-
late CC50, EC50, and IC50 values. The selectivity index (SI) was defined as
the ratio of CC50 (macrophages) to IC50 (amastigote form). One-way
analysis of variance (ANOVA) and Bonferroni multiple comparison tests
were used to determine the statistical significance of group comparisons
in the in vitro infection assay, and two-way ANOVA with Bonferroni
FIG 1 Ruthenium complexes 1 to 4. (A) Representation of the complexes: cis-[RuCl(NO2)(dppb)(5,5-mebipy)] (1), cis-[Ru(NO2)2(dppb)(5,5-mebipy)]
(2), ct-[RuCl(NO)(dppb)(5,5-mebipy)](PF6)2 (3), cc-[RuCl(NO)(dppb)(5,5-mebipy)](PF6)2 (4). N-N is 5,5=-dimethyl-2,2=-bipyridine (5,5=-mebipy),
and P-P is 1,4-bis(diphenylphosphino)butane (dppb). (B) ORTEP-3 view of complex 2 and the atom numbering scheme. Ellipsoids are drawn at the 30%
probability level.
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multiple comparison tests was used in the in vivo assay (parasitemia).
Results were considered statistically significant whenP values were0.05.
Analyses were performed using GraphPad Prism version 5.01 (Graph Pad
Software, San Diego, CA, USA) and OriginPro version 8.5 (OriginLab,
Northampton,MA,USA) (cruzain IC50s only). Animal survival rateswere
analyzedwithGraphPad Prism 1.5 (GraphPad Software). Combined drug
analysis was calculated by using CompuSyn (ComboSyn, Inc., Paramus,
NJ, USA).
RESULTS
Compound characterization. Figure 1A shows the structures of
ruthenium complexes investigated here. Complex 1 is the proto-
type compound, since it was used as the basis for synthesis of all
other compounds. The differences among the complexes are
based on the presence or absence of the nitro/nitrosyl group or
chlorine. Complex 1 has a nitro group and a chlorine ligand; com-
plex 2 was formed by replacing the chlorine by a nitro group.
Complexes 3 and 4 are nitrosyl species. The difference between
complexes 3 and 4 is the NO position; in complex 3, the NO is cis
to chlorine and trans to phosphorus atoms, whereas in complex 4,
NO is cis to chlorine and cis to phosphorus atoms.
All complexeswere subjected to chemical and spectroscopic anal-
ysis. The elemental composition (C, H, and N) of the complexes
corresponded closely to the calculated values. The 31P{1H} nuclear
magnetic resonance (NMR) spectra of complexes 1 to 4 exhibited a
pair of doublets that indicated the magnetic inequivalence of the
phosphorus atoms present in the dppb (30). The observed doublets
showed chemical shifts different from those of the starting material
cis-[RuCl2(dppb)(5,5=-mebipy)], suggesting that the presence of the
nitro or nitrosyl groups coordinated to themetal shifted the electron
density of the phosphorus atoms from the dppb.
In the infrared (IR) spectrum of cis-[RuCl(NO2)(dppb)(5,5=-
mebipy)] (complex 1), there were strong bands at 1,349 cm1 and
1,298 cm1, which can be assigned to 	asNO2 and 	sNO2, respec-
tively. For cis-[Ru(NO2)2(dppb)(5,5=-mebipy)] (complex 2), these
bands were at 1,360 cm1 and 1,310 cm1 for 	asNO2 and at 1,294
cm1 and 1,269 cm1 for 	sNO2. The presence of four bands for
this complex indicates that nitro groups are nonequivalent, one
being trans to the nitrogen of 5,5=-mebipy, while the other is trans
to the phosphorus of dppb. The nitrosyl complexes ct-[RuCl
(NO)(dppb)(5,5-mebipy)](PF6)2 (complex 3) and cc-[RuCl-
(NO)(dppb)(5,5-mebipy)](PF6)2 (complex 4) exhibited strong
bands at 1,891 cm1 and at 1,895 cm1, respectively, which were
assigned to the NO
 stretching (31). Nitro group can be bound to
metal through either nitrogen or oxygen, whichmay produce geo-
metric isomers (32). Complex 1 exhibits its wNO2 band at 572
cm1, while complex 2 has two bands, at 566 and 610 cm1, sug-
gesting that in both complexes the nitro group is bound to the
ruthenium through the nitrogen atom (32, 33). In addition to IR,
the electronic absorption spectra for all complexes were charac-
terized by an intense high-energy band centered at about 300 nm,
which can be assigned to an intraligand –* transition. Also,
these complexes exhibited low-energy bands in the range of 316 to
488 nm, which can be assigned to a metal-to-ligand charge trans-
fer (MLCT) transition, Ru (d) to ligand (*).
The crystal structure of complex 2 was solved by X-ray crystal-
lography (Table 1), and its ORTEP view was prepared with
ORTEP-3 for Windows (Fig. 1B). Selected bond lengths (Å) and
angles (°) in the complex are listed in Table S1 in the supplemental
material. Complex 2 exhibits a distorted octahedral geometry, and
it crystallized in a triclinic system, space group P-1, with themetal
center coordinated to two bidentate ligands and two NO2 groups.
The nitro groups are cis-positioned relative to each other and co-
ordinated through the nitrogen atoms, as suggested by the IR data.
From the data in Table S1, it can be seen that the Ru-N(NO2) [Ru-
N(NO2) trans P] bond length is about 0.5 Å longer than the bond
Rui-N(2) [Ru-N(NO2) transN(bipy)], which is consistent with the
stronger trans effect of the phosphorus atoms, relative to the
trans effect of the nitrogen atoms. Also, this difference explains
the two bands for 	NO2 observed in the infrared spectrum of
complex 2.
Anti-T. cruzi activity and host cell cytotoxicity. Anti-T. cruzi
activity was determined in epimastigotes and trypomastigotes of
the Y strain, and results were expressed as IC50 and EC50, respec-
tively. Cell toxicity in BALB/c mice macrophages was performed
under identical drug incubation times for antiparasitic assay in
trypomastigotes (i.e., 24-h drug exposure) and expressed as CC50.
Benznidazole was used as the reference drug in these assays, and
results are reported in Table 2. Benznidazole exhibited an IC50 of
10.7  1.6 M in epimastigote proliferation. Similarly, it was
observed that ruthenium complexes 2, 3, and 4 greatly inhibited
TABLE 1 Crystal data and structure refinement of complex 2
Characteristic Value
Empirical formula [RuC42H46N4O5P2]·CH3CH2OH
Formula wt 849.84
Temp (K) 293(2)
Wavelength (Å) 0.71073
Crystal system Triclinic
Space group P-1
Unit cell dimensions
a (Å) 10.2261(7)
b (Å) 12.2153(5)
c (Å) 17.4217(10)
 (°) 74.904(2)
 (°) 74.660(3)
 (°) 76.827(3)
Vol (Å3) 1996.5(2)
Z 2
Density (calculated) (mg/m3) 1.414
Absorption coefficient (mm1) 0.522
F(000) 880
Crystal size (mm3) 0.30 by 0.26 by 0.10
Theta range for data collection (°) 3.13 to 26.41
Index ranges 11 h 12,15 k 15,
21 l 21
No. of reflections collected 15,073
No. of independent reflections 8,129 [R(int) 0.0217]
% completeness to theta 25.00° 99.0
Absorption correction Gaussian
Max and min transmission 0.950 and 0.847
Refinement method Full-matrix least-squares on F2
Computing COLLECT, HKL Denzo and Scalepack,
SHELXL-97, SHELXS-97a
Data/restraints/parameters 8,129/2/491
Goodness of fit on F2 1.056
Final R index [I 2(I)] R1 0.0378, wR2 0.1010
R index (all data) R1 0.0442, wR2 0.1045
Largest diff peak and hole (e Å3) 0.611 and0.640
a Data collection, data processing, structure solution, and structure refinement,
respectively.
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epimastigotes. In contrast, complex 1 did not inhibit epimastigote
proliferation. Complexes 1 to 4 decreased trypomastigote viabil-
ity, with EC50s lower than that of benznidazole. Complex 5, which
lacks a nitro/nitrosyl group, did not exhibit antitrypomastigote
activity, while complex 3 was the most active compound among
them, with an EC50 of 2.1 0.6 M. Complexes 1 and 5 did not
demonstrate cytotoxicity in macrophages following the drug ex-
posure, and complex 2 displayed relatively low cytotoxicity. Com-
plexes 3 and 4 had CC50 values of 28.5 2.0 and 25.4 0.1 M,
respectively.
Evaluation of cruzain inhibition.Due to the previous findings
that ruthenium complexes inhibit cruzain, inhibitory activity was
measuredhere forallfivecomplexes inanassaybasedoncompetition
with Z-Phe-Arg 7-amido-4-methylcoumarin hydrochloride (Z-FR-
AMC). (2S,3S)-trans-Epoxysuccinyl-L-leucylamido-3-methylbutane
(E-64c), which is a high-affinity cruzain inhibitor, was used as the
reference inhibitor and displayed an IC50 of 1.0 0.8 nM. As dem-
onstrated in Table 2, complex 2 did not inhibit cruzain, while com-
plexes 1 and 5 presented weak potency, with IC50s as high as 30M.
Complexes 3 and 4 showed stronger potency against cruzain, with
IC50sof14.46.6and0.40.1M,respectively.Althoughcomplex
4was themost potent rutheniumcomplex, it had lowerpotency than
E-64c.
In vitro infection. After observing that ruthenium complexes
inhibit the extracellular parasite, we investigated their activity
against the intracellular parasite. It was observed that all the nitro/
nitrosyl complexes at 10 M caused a statistically significant re-
duction in the percentage of T. cruzi-infected macrophages com-
pared to untreated infected cells (Fig. 2A). Complex 3 was the
most potent of the four compounds tested in reducing the in vitro
infection. Additionally, all the complexes decreased the mean
number of intracellular parasites (Fig. 2B) as well as the parasite
burden (Fig. 2C). Amastigote IC50 was calculated by analyzing the
percentage of infected cells (Table 3). Ruthenium complex 3
greatly inhibited this percentage, displaying an IC50 of 1.3  0.2
M, while benznidazole displayed an IC50 of 14.0 0.3 M. Cy-
totoxicity of ruthenium complexes incubated for 6 h in macro-
phages demonstrated that neither benznidazole nor complex 1 are
cytotoxic at the tested concentrations (CC50s of100M). Com-
plex 2 exhibited a low cytotoxicity (CC50 93.1 7.7 M), and
complexes 3 and 4were approximately 2-foldmore cytotoxic than
TABLE 2 Antiparasitic activity, host cell cytotoxicity, and cruzain
inhibition of ruthenium complexes 1 to 5e
Compound
T. cruzi Y strain
Macrophage
CC50 SEM
(M)c
Cruzain
IC50 SD
(M)d
Epimastigote
IC50 SEM
(M)a
Trypomastigote
EC50 SEM
(M)b
Complex 1 100 8.4 1.1 100 30.2 7.3
Complex 2 16.6 0.6 2.9 0.2 50.5 0.1 100
Complex 3 5.7 0.6 2.1 0.6 28.5 2.0 14.4 6.6
Complex 4 26.7 2.0 5.9 1.0 25.4 0.1 0.4 0.1
Complex 5 ND 100 100 59.8 4.6
Bdz 10.7 1.6 11.4 1.0 100
E-64c 1.0 0.8 nM
a Determined 5 days after incubation with complexes.
b Determined 24 h after incubation with complexes.
c Cell viability of BALB/c mouse macrophages determined 24 h after treatment.
d Cruzain activity was determined 10 min after incubation.
e Values were calculated using concentrations in triplicate, and two independent
experiments were performed. IC50, inhibitory concentration at 50%; EC50, effective
concentration at 50%; CC50, cytotoxic concentration at 50%; ND, not determined
owing to lack of activity; Bdz, benznidazole; E-64c, standard cruzain inhibitor.
FIG 2 Ruthenium complexes reduce the in vitro infection. (A) Percentage of infection in comparison to untreated infected cells; (B) percentage of amastigotes/
100 macrophages in comparison to untreated controls; (C) parasite burden, calculated as the percentage of infected cells the mean number of amastigotes.
Infected macrophages were treated for 6 h and then incubated for 4 days. Three independent experiments were performed. Error bars represent the standard
errors of the means. ***, P 0.0001 compared to untreated controls.
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nitro complex 2. The selectivity index (SI) of the ruthenium com-
plexes was calculated, and it was observed that, among the com-
plexes tested, complex 3 showed the highest SI.
NO level in infected cells.Complex 3 was themost potent and
selective antiparasitic ruthenium complex. To investigate whether
complex 3 is an NO donor drug, NO levels in infected macro-
phages were inferred by determining nitrite content. In this assay,
infected cells were incubated for 24 h with drugs, and the nitrite
content was estimated by the Griess method. As shown in Fig. 3A,
untreated infected BALB/c macrophages produced low levels of
NO, whereas stimulus with IFN- and LPS induced a significant
production of NO. In comparison to untreated infected cells,
treatment with 10 M complex 3 presented a significantly eleva-
tion inNO (P 0.001). In contrast, treatment with complex 5 did
not result in significant production of NO. No measurable NO
concentration was observed in a cell-free experiment containing
only complex 3 plus culture medium (data not shown). The same
conditions were used in infected J774 cell lines, and similar results
were observed (Fig. 3B).
Electron microscopy analysis. Trypomastigotes were treated
with complex 3 and analyzed by scanning electron microscopy
(SEM). In comparison with untreated parasites (Fig. 4A), treat-
ment resulted in parasite shrinkage and caused cell membrane
discontinuity and fragmentation (Fig. 4B). Morphological
changes following complex 3 treatment were observed in 76% of
the parasite cells. Among these cells, 74% showed cell shrinkage,
21% displayedmembrane discontinuity, and 21% hadmembrane
fragmentation (data not shown). Next, transmission electron mi-
croscopy (TEM) experiments were performed in trypomastigotes
and intracellular amastigotes. In comparison with untreated try-
pomastigotes (Fig. 4C), parasites in the presence of complex 3
exhibited swollen mitochondria (Fig. 4D) and loss of the nuclear
membrane (Fig. 4E). In most of the treated trypomastigotes, the
presence of atypical cytoplasmic vacuoles and the formation of
myelin-like structures (Fig. 4F) were observed. The presence of
these atypical cytoplasmic vacuoles was also observed in intracel-
lular amastigotes following treatment with the ruthenium com-
plex (Fig. 4H).
Autophagymarkers.Theobservations by transmissionmicro-
graphs that ruthenium complex induces the formation of atypical
cytoplasmic vacuoles led us to investigate whether themechanism
of action involves autophagy. Trypomastigotes were treated with
the complex 3 and then incubated with monodansylcadaverine
(MDC) to label the autophagic cytosolic vacuoles. In this experi-
ment, untreated parasites were not stained with MDC (Fig. 5A),
while parasites treated with rapamycin, a standard autophagy in-
ducer, were stained (Fig. 5B). Parasites treated with complex 3
were positively stained with MDC (Fig. 5C). In order to distin-
guish between autophagic and lysosomal vacuoles, an additional
experiment was carried out using the autophagy inhibitor wort-
mannin. MDC staining during complex 3 treatment was blocked
in the presence of 0.5 Mwortmannin (data not shown). The pres-
ence of microtubule-associated protein 1b light chain 3 (LC3B) was
detected in untreated and treatedT. cruzi-infected macrophages by
incubating with anti-LC3B polyclonal antibody. In this controlled
experiment, nuclei were stained with 4=,6-diamidino-2-phenylin-
dole (DAPI), and cells were analyzed by immunofluorescence un-
der a confocal microscope. Untreated infected macrophages did
not demonstrate LC3B labeling (Fig. 5A). In contrast, infected
macrophages treated with 0.1 mg/ml rapamycin displayed intra-
cellular parasites labeled for LC3B (Fig. 5B). Similarly, infected
macrophages treated with ruthenium complex 3 at 2.1 M dis-
played intracellular parasites labeled for LC3B (Fig. 5C).
Parasite cell death.After observing that ruthenium complexes
induce autophagy, we wanted to know the consequence of au-
TABLE 3 Antiparasitic activity in intracellular parasite, host cell
cytotoxicity, and selectivity index of ruthenium complexes 1 to 5d
Compound
Amastigote IC50
SEM (M)a
Macrophage CC50
SEM (M)b SIc
Complex 1 4.2 1.6 100 24
Complex 2 2.6 0.7 93.1 7.7 36
Complex 3 1.3 0.2 51.4 0.2 40
Complex 4 2.7 0.6 38.3 2.3 14
Complex 5 ND 100 ND
Bdz 14.0 0.3 100 7
a Cells were exposed to complexes for 6 h, and activity was determined 4 days after
incubation with complexes.
b Cell viability of BALB/c mouse macrophages determined 6 h after treatment.
c SI is selectivity index, calculated by the ratio of CC50 (macrophages) to IC50
(amastigotes).
d IC50 and CC50 values were calculated using concentrations in triplicate, and two
independent experiments were performed. IC50, inhibitory concentration at 50%;
CC50, cytotoxic concentration at 50%; ND, not determined owing to lack of activity;
Bdz, benznidazole.
FIG 3 Ruthenium complex 3 increases NO in infected macrophages. Nitrite levels in infected macrophages determined 24 h after treatment. BALB/c peritoneal
(A) and J774 (B)macrophageswere infectedwith trypomastigotes and treatedwith 10Mof complexes 3 and 5. A positive-control culture (
ctr) was stimulated
with IFN- and LPS. The negative-control culture (ctr) received no treatment or stimulus. Nitrite contents in the supernatant were estimated by the Griess
nitrite test 24 h later. Values represent the means SEM from three independent experiments. ***, P 0.0001 compared to negative control; **, P  0.001
compared toctr.
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tophagy to the parasite cells. To this end, trypomastigotes were
incubated with two different concentrations (2.5 and 5.0 M) of
complex 3 for 36 h at 37°C and then double labeled with annexin
V-fluorescein isothiocyanate (FITC) and propidium iodide (PI).
Individual cell data were acquired and analyzed by flow cytom-
etry. In comparison to untreated parasites (Fig. 6A), a concentra-
tion-related increase in the percentage of stained parasites was
observed after complex 3 treatment (Fig. 6B and C). Parasites
treatedwith complex 3 at 5.0Mshowed 34.6%positively stained
cells, of which 26.1%were necrotic (PI stain alone), 5.6%were late
apoptotic (PI-annexin V), and 2.9% were early apoptotic (an-
nexin staining alone). As shown in Fig. 6D, this ruthenium com-
plex significantly increased the proportion of necroticT. cruzi cells
in a concentration-dependent manner.
In vivo efficacy study. Complex 3 was tested in T. cruzi-in-
fected mice during the acute phase. Control groups, receiving ei-
ther benznidazole or vehicle, were included in this experiment. In
this assay, 104 Y strain trypomastigotes in a 100-l solution were
FIG 4 Ruthenium complex 3 causes irreversible morphological impairments to the parasite. Scanning electron micrograph in panel A shows untreated
trypomastigote, and panel B shows treated parasite. Transmission electron micrographs in panels C to F are trypomastigotes and in panels G and H are infected
macrophages. Panel C shows untreated trypomastigotes, panels D to F are treated parasites. Arrow in panel D indicates cytoplasmic vacuoles; arrow in panel E
indicates mitochondrial swelling; arrow and asterisk in panel F indicate nuclear membrane disruption and myelin-like figures, respectively. Panel G shows
untreated infected cells, while panel H shows treated infected cells. Arrow in panel H indicates cytoplasmic vacuoles. Complex 3 was added at 2.1 M and
incubated for 24 h in trypomastigotes and 6 h in infected macrophages. GA, Golgi apparatus; K, kinetoplast; N, nucleus; M, mitochondria.
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intraperitoneally inoculated in female BALB/c mice (n 
6/group). Treatments were given orally by gavage. Blood para-
sitemia and survival rates were analyzed. Complex 3 at 25 and 75
mol/kg was able to decrease the blood parasitemia peak by 25%
(P 0.001) and 46% (P 0.001), respectively (Fig. 7A), in com-
parison to the blood parasitemia in the untreated group. On day
12 postinfection, no parasites were detected bymicroscopic exam-
ination in benznidazole group blood samples, indicating negative
parasitemia. But the same was not observed for infected mice re-
ceiving 75mol/kg of complex 3. Mice mortality rates were mon-
itored up to 30 days postinfection. Complex 3 at 75 mol/kg sig-
nificantly decreased mortality compared to that of the untreated
group (log rank, P 0.01). The group treated with benznidazole
had 100% survival, while the group treated with the highest dose
of complex 3 showed a survival rate of 50% (Fig. 7B).
Drug combination. Considering that complex 3 and ben-
znidazole exhibit differentmechanism of antiparasitic actions, the
possibility of drug combination was studied. Complex 3 and ben-
znidazole alone or in fixed combinations were evaluated against
trypomastigote cell cultures, and results were analyzed by Com-
puSyn software and listed in Table 4. In comparison to individual
drug incubation, the combination of complex 3 and benznidazole
reduced both EC50 and EC90 values. Combination index (CI) cal-
culations were used as cutoffs and revealed that this combination
has synergistic effects against trypomastigotes. It was observed
that drug combinations at the EC50s reduced the percentage of
viable trypomastigotes (Fig. 7C) but did not reduce the percentage
of viable macrophages (Fig. 7D). Of note, macrophage cytotoxic-
ity was observed when drug combinations were evaluated in con-
centrations equal or higher than the EC90 values.
Based on the in vitro synergism, we evaluated the efficacy of
ruthenium complex 3 in combination with a suboptimal dose of
benznidazole. Complex 3 at 75 mol/kg (80 mg/kg) and ben-
znidazole at 38 mol/kg (10 mg/kg) were administered individu-
ally or in combination using the in vivo protocol described above.
Benznidazole at this suboptimal dose reduced blood parasitemia
compared to that of the untreated group but did not eliminate
circulating parasites. The group receiving the drug combination
presented lower parasitemia than the untreated group and groups
receiving each individual drug (Fig. 7E). When monitored for up
to 30 days postinfection, the group treatedwith drug combination
had 100% survival, while the groups treated with each drug alone
showed a survival rate of 60% (Fig. 7F).
DISCUSSION
Identification of new pharmaceuticals is vital for Chagas disease
treatment. In order to reach this objective, investigations cannot
be limited to small organic molecules but should also include me-
tallic compounds. In fact, coordination complexes and organo-
metallics are recognized as notable anti-T. cruzi agents. For in-
stance, the coordination of trypanocidal molecules with metals
increases anti-T. cruzi activity in comparison with the metal-free
molecules. This enhanced activity can be explained by the gain in
lipophilicity. This strategy has been performed to enhance the
potency of ketoconazole, clotrimazole, benznidazole, risedronate,
and quinolones (34–39). Alternatively,metal complexeswhich are
composed of ligands with unique chemical properties (redox and
electrochemical behavior based on ligand reductions) exhibit an-
ti-T. cruzi properties, possibly due to parasitemembrane accumu-
lation, in addition to effects on DNA and enzymes (40–43).
Here, the in vitro screening of anti-T. cruzi activity demon-
strated that both nitro andnitrosyl rutheniumcomplexes are toxic
for trypomastigotes and inhibited epimastigote proliferation at
noncytotoxic concentrations in host cells. In contrast, the ruthe-
nium complex lacking nitro and nitrosyl groups did not display
anti-T. cruzi activity. Regarding structure-activity relationships,
the complex containing two nitro groups was more potent than
the complex containing only one. However, the nitrosyl com-
plexes showed greater activity than nitro complexes. This suggests
that a nitrosyl group contributes more to antiparasitic activity
FIG 5 Ruthenium complex 3 induces parasite autophagy. Panel A shows untreated parasites, panel B shows treatment with 0.1 mg/ml rapamycin, and panel C
is treatment with 2.1 M ruthenium complex 3. Axenic trypomastigotes were incubated for 24 h and stained with MDC, and infected macrophages were
incubated for 6 h and then stained with anti-LC3B antibody and DAPI. Images were captured using a confocal microscope with a 60 oil-immersion objective
at3 zoom. DIC, differential interference contrast.
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than a nitro group. For cruzain, nitro complexes exhibitedweak or
no inhibitory activity, while nitrosyl complexes exhibited greater
inhibitory activity. The nitrosyl complex 4 was only twice less
potent as an antiparasitic than its isomer, complex 3, but it pre-
sented much higher potency against cruzain than complex 3.
These observations indicate that the environment surrounding
the metal is important for biological activity.
After determining that these ruthenium complexes inhibit ex-
tracellular T. cruzi, we examined their activity in infected macro-
phages. The complexes were able to reduce the number of infected
cells more efficiently than benznidazole, and they clearly arrested
parasite growth and differentiation inside the host cells. Given the
potency of complex 3 against amastigotes, we investigated its
mechanism of action in parasites. We observed that nitrosyl com-
plex 3 increased the NO levels in infected macrophages, while the
complex lacking the nitrosyl group did not. The antiparasitic ac-
tivity of ruthenium complex 3 is likely due to its NO-releasing
ability or alternatively by indirectly inducing NO production. Ac-
cording to the literature,NO release leads to the inactivation of the
protease cruzain in parasite cells. However, complex 3 did not
present potency as strong as the powerful cruzain inhibitor E-64c.
Therefore, we believe that while complex 3 is an NO donor drug,
this property is not related to its ability to inhibit cruzain. Further
evidence regarding the mechanism of action of complex 3 was
found by analyzing the parasite ultrastructure and morphology.
Two main effects were observed in the treated parasites: first, cell
membrane discontinuity and fragmentation and, to a lesser ex-
tent, nuclear membrane alterations; second, the appearance of
atypical cytoplasmic vacuoles, as well as the formation of myelin-
like figures.
Lack of cell membrane integrity is very often associated with
necrotic parasite death (44). In fact, parasites treated with com-
plex 3 exhibited a cell death pattern via necrosis rather than apop-
tosis. Our results are consistent with previous findings demon-
strating that ruthenium bipyridyl complexes are prone to
accumulate in the cell membrane (22). The presence of cytoplas-
mic vacuoles and myelin-like figures suggested that ruthenium
complexes induce parasite autophagy. By assaying MDC staining
and LC3B immunolocalization (45, 46), it was observed that try-
pomastigotes were stained with MDC after ruthenium complex
treatment, and this process was blocked by the presence of the
autophagy inhibitor wortmannin. Similar to the literature (47,
48), here, ruthenium complex treatment resulted in the accumu-
lation of LC3B in intracellular amastigotes. The findings observed
here support the overall idea that nitrosyl-ruthenium complexes
release NO, which triggers cellular events, including parasite au-
tophagy. As a result, a number of irreversible morphological im-
FIG 6 Ruthenium-based treatment causes parasite death by inducing necrosis. Trypomastigotes were treated with complex 3 for 36 h. Parasites were examined
by flow cytometry with annexinV and PI staining. Cells plotted in each quadrant represent the following: lower left, double negative; upper left, PI single positive;
lower right, annexin V single positive; upper right, PI and annexin V double positive. (A) Untreated; (B) complex 3 at 2.5 M; (C) complex 3 at 5.0 M; (D)
percentage of PI-positive cells. Values are means SD from triplicate tests.ctr, negative control. **, P 0.05 compared to negative control (ANOVA);
***, P  0.0001 compared to negative control (ANOVA).
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pairments occur to the parasite cells, finally leading to cell death by
necrosis.
Due to the strong antiparasitic activity of complex 3, it was
evaluated in mice during the acute phase of Chagas disease. Com-
plex 3 had a dose-dependent effect and presented an optimal effi-
cacy when given orally at 75 mol/kg. This reduced the blood
parasitemia and increasedmice survival; however, it did not elim-
inate parasites present in the bloodstream, while the benznidazole
regime did. Given the substantial dedication to identifying opti-
mal drug combinations for the treatment of Chagas disease (49,
50), a combination of ruthenium complex 3 and benznidazole
would offer a potential therapy to reduce the benznidazole dosage
required to cure infection. This is supported by the fact that com-
bination would target T. cruzi at two different modes of action:
FIG 7 Ruthenium complex 3 reduces acute infection, and this is enhanced under drug combination with benznidazole. Parasitemia (A) and survival (B) of T.
cruzi-infected mice (n  6/group) orally treated once per day for 5 consecutive days with 25 mol/kg (26.6 mg/kg) or 75 mol/kg (80 mg/kg) of complex 3.
Benznidazole (Bdz) was given at 384 mol/kg (100 mg/kg). (A) Sets a, b, c, vehicle versus Bdz (P 0.001), vehicle versus complex 3 at 25 mol/kg (P 0.001),
vehicle versus complex 3 at 75 mol/kg (P 0.001), respectively. (B) Log rank analysis, vehicle versus complex 3 at 75 mol/kg (P 0.01), vehicle versus Bdz
(P 0.001). Percentage of viable trypomastigotes (C) andmacrophages (D). Drug concentration is indicated on the x axis inM, and cell viability was recorded
24 h after incubation. (E) Parasitemia and survival of infected mice (n  6/group) orally treated once per day with a drug combination of complex 3 and
benznidazole. (a) Vehicle versus complex 3 (P 0.001), vehicle versus Bdz (P 0.01), vehicle versus drug combination (P 0.001); (b) vehicle versus complex
3 (P  0.05), vehicle versus drug combination (P  0.001); (c) vehicle versus complex 3 (P  0.05), vehicle versus Bdz (P  0.001), vehicle versus drug
combination (P 0.001). (F) Log rank analyses revealed curves are not significantly different.
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NO release and autophagy induction mediated by complex 3 and
nitroreductase inhibition and oxidative stress inductionmediated
by benznidazole (51, 52). In vitro, combinations of complex 3 and
benznidazole were synergic in killing trypomastigotes. In infected
mice, combination of ruthenium complex with a suboptimal dose
of benznidazole exhibited enhanced efficacy in terms of reducing
infection and increasing survival compared to each drug used
alone. Overall, these findings indicate that ruthenium complexes
are a class of suitable constituents for drug combination.
Conclusions. We investigated the NO donor drug strategy by
synthesizing new ruthenium complexes that feature nitro or ni-
trosyl groups. These complexes exhibited a broad spectrum of
activities (vector-borne stage, bloodstream form, intracellular
stage) against T. cruzi. This activity is abolished once nitro and
nitrosyl groups are removed from the complex, indicating these
groups are structural determinants for activity. By examining the
underlying mechanism of action of these complexes, it was ob-
served that they release NO, causing autophagy, which is followed
by a series of irreversible morphological impairments to the par-
asites, culminating in necrotic cell death. More striking, rutheni-
um-nitrosyl complex 3 was efficient in reducing blood para-
sitemia in acutely infected mice and presented synergic effects
when in combination with benznidazole.
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MATERIALS AND METHODS 
 
Instrumentation and reagents: 
31
P{
1
H} NMR experiments were carried out at 293 K in a Bruker 
spectrometer (XRD 400 MHz, 9.4 T, Billerica, MA, USA) with CDCl3 as solvent and 85 % H3PO4 as 
external reference. The splitting of the phosphorus resonance was defined as a d ¼ doublet. Infrared spectra 
were collected in a FT MB-102 spectrometer (Bomem–Michelson Inc, Newark, NJ, USA), with KBr sample 
pellets, in the range 4000-200 cm
-1
. UV-visible (UV-Vis) spectra were recorded in a diode-array 
spectrophotometer (model HP8452A, HP, Santa Clara, CA, USA). Elemental analysis (C, H and N contents) 
was performed in a Fisions Instrument EA1108 CHNS microanalyzer at the Microanalytical Laboratory of 
Universidade Federal de São Carlos (São Carlos, Brazil). All chemicals used were analytical grade reagents 
or of comparable purity. RuCl3·3H2O, 1,4-bis(diphenylphosphino)butane (dppb), 5,5’–dimethyl-2,2’–
bipyridine (5,5’–mebipy), sodium nitrite, potassium hexafluorophosphate, hexafluorophosphoric acid and 
hydrochloro acid were acquired from Sigma-Aldrich (St. Louis, MO, USA). The starting material cis–
[RuCl2(dppb)(5,5’–mebipy)] and cis–[RuCl2(dppb)(mebipy)] (1) were prepared as described in previous 
publications (1-3). 
 
Synthesis of the complexes: 
(1) cis-[RuCl(NO2)(dppb)(5,5’-mebipy)] 
In a 50 mL round-bottom flask, 0.25 mmol (200 mg) of cis-[RuCl2(dppb)(5,5’–mebipy)] was dissolved in 20 
mL of methanol and allowed to react with an excess of sodium nitrite (0.76 mmol), under argon an 
atmosphere. After 1 h of stirring, an orange precipitate was formed, which was filtered off, washed with 
water, methanol and diethyl ether (10 mL) and dried under vacuum. Yield = 82 %. Anal. Calcd for 
C40H40ClN3O2P2Ru: C, 60.37; H, 5.08; N, 5.30. Found: C, 60.57; H, 5.27; N, 5.44. 
31
P{
1
H} NMR (, ppm): 
34.3 (d); 31.2 (d), 
2
JP-P ¼ = 24.3 Hz. UV-Vis (CHCl3; 1.0 x 10
-5 
M): /nm (/M-1cm-1) 314 (1.04 x 10-4), 410 
(0.16 x 10
-4
), 488 (0.075 x 10
-4
). 
(2) cis-[Ru(NO2)2(dppb)(5,5’-mebipy)] 
In a 50 mL round-bottom flask, 50 mg (0.064 mmol) of cis-[RuCl(NO2)(dppb)(5,5’-mebipy)] (1) was 
dissolved in 40 mL of 1:3 methanol/chloroform mixture and an excess of sodium nitrite (0.38 mmol) was 
added, the mixture being stirred and maintained under an argon atmosphere for 3 h. The solvent was 
removed under reduced pressure to about 2 mL and previously degassed diethyl ether (25 mL) was added, 
precipitating a yellowish solid, which was filtered off, washed with water and diethyl ether (10 mL) and 
dried under vacuum. Yield = 88 %. Anal. Calcd for C40H40N4O4P2Ru: C, 59.77; H, 5.02; N, 6.97. Found: C, 
59.36; H, 5.38; N, 7.01. 
31
P{
1
H} NMR (, ppm): 45.5 (d); 25.0 (d), 2JP-P ¼ = 24.3 Hz. UV-Vis (CHCl3; 10
-5 
M): /nm (/M-1cm-1) 306 (0.87 x 10-4), 400 (0.16 x 10-4). 
(3) ct-[RuCl(NO)(dppb)(5,5’-mebipy)](PF6)2  
In a 50 mL round-bottom flask, 50 mg (0.06 mmol) of cis-[RuCl(NO2)(dppb)(5,5’-mebipy)] (1) was 
dissolved in 20 mL ethanol and an excess of hexafluorophosphoric acid (HPF6, 1 mL) was added under 
argon an atmosphere and the mixture stirred for 30 minutes. The volume of the pale brown solution was 
reduced to about 2 mL and then 20 mL of water was added to precipitate a pale brown solid, which was 
filtered off, washed with water and diethyl ether (10 mL) and dried under vacuum. Yield = 94 %. Anal. 
Calcd for C40H40ClN3OP4F12Ru: C, 45.02; H, 3.78; N, 3.94. Found: C, 44.79; H, 3.55; N, 4.00. 
31
P{
1
H} 
NMR (, ppm): 26.9 (d); 17.1 (d), 2JP-P ¼ = 36.4 Hz. UV-vis (CHCl3; 1.0 x 10
-5 
M): /nm (/M-1 cm-1) 256 
(1.60 x 10
-4
), 324 (0.67 x 10
-4
), 362 (0.18 x 10
-4
). 
(4) cc-[RuCl(NO)(dppb)(5,5’-mebipy)](PF6)2  
In a 50 mL round-bottom flask, 50 mg (0.06 mmol) of cis-[Ru(NO2)2(dppb)(5,5’-mebipy)] (2) dissolved in 
20 mL ethanol was stirred with an excess of hydrochloro acid (HCl,  mL) under an argon atmosphere for 30 
minutes. The volume of the beige solution was then reduced to about 2 mL and, after addition of solution of 
25 mg KPF6 in 20 mL of water, a beige material was precipitated, which was filtered off, washed with water 
and diethyl ether (10 mL), and dried under vacuum. Yield = 93 %. Anal. Calcd for C40H40ClN3OP4F12Ru: C, 
45.02; H, 3.78; N, 3.94. Found: C, 44.55; H, 4.12; N, 4.14. 
31
P{
1
H} NMR (, ppm): 26.0 (d); 22.6 (d), 2JP-P 
¼ = 14.9 Hz. UV-vis (CHCl3; 1.0 x 10
-5 
M): /nm (/M-1cm-1) 304 (1.20 x 10-4), 316 (0.10 x 10-4), 352 (0.39 
x 10
-4
). 
X-ray crystallography: Yellowish crystals of cis-[Ru(NO2)2(dppb)(5,5’-mebipy)] (2) were grown by slow 
evaporation of a solution in a 1:1 mixture of dichloromethane/ethanol. The crystal was mounted on a 
goniometer in a Enraf-Nonius Kappa-CCD diffractometer and analyzed with graphite-monochromated Mo-
Ka (l ¼ 0.71073 Å) radiation. The final unit-cell parameters were based on all reflections. Data were 
collected with the program COLLECT (4). Integration and scaling of the reflections were performed with 
the software package HKL DENZO-SCALEPACK (5). A semi-empirical absorption correction was applied 
(6). The structure was solved by direct methods with SHELXS-97 (7). The model was refined by full-matrix 
least squares on F
2
, carried out with SHELXL-97 (8). Hydrogen atoms were stereochemically positioned and 
refined with a riding model. Hydrogen atoms on the aromatic rings were refined isotropically, each with a 
thermal parameter 30 % greater than the equivalent isotropic displacement parameter of the atom to which it 
was bonded. The crystal structure of cis-[Ru(NO2)2(dppb)(5,5’-mebipy)] (2) was visualized in ORTEP-3 (9). 
 
Table S1. Selected bond lengths (Å) and angles (
0
) for the cis-[Ru(NO2)2(dppb)(5,5`-Mebipy)] complex (2). 
bond lengths (Å) bond angles (o) 
Ru(1)-N(2); Ru-N(NO2) trans N(bipy) 2.051(2) N(2)-Ru(1)-N(1) 90.93(8) 
Ru(1)-N(1); Ru-N(NO2) trans P 2.103(2) N(1)-Ru(1)-N(3) 83.02(8) 
Ru(1)-N(3); Ru-N(bipy) trans P 2.135(2) N(2)-Ru(1)-N(3) 91.27(8) 
Ru(1)-N(4); Ru-N(bipy) trans NO2 2.142(2) N(2)-Ru(1)-N(4) 167.33(8) 
Ru(1)-P(2); Ru-P trans N(bipy) 2.3787(6) N(3)-Ru(1)-P(2) 176.55(6) 
Ru(1)-P(1); Ru-P trans N(NO2) 2.4031(6) N(2)-Ru(1)-P(1) 89.13(6) 
O(1)-N(1) ; O(1)-N trans P 1.237(3) O(1)-N(1)-Ru(1) 120.20(18) 
O(2)-N(1); O(2)-N trans P 1.233(3) O(2)-N(1)-Ru(1) 120.20(18) 
O(3)-N(2); O(3)-N trans N(bipy) 1.224(3) O(3)-N(2)-Ru(1) 123.18(17) 
O(4)-N(2); O(4)-N trans N(bipy) 1.253(3) O(4)-N(2)-Ru(1) 118.77(17) 
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